Meyahealth
HomeGeneticsConditionSepto-optic dysplasia
Back to Condition
Septo-optic dysplasia
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Septo-optic dysplasia

Septo-optic dysplasia is a rare disorder affecting early brain development, characterized by a combination of optic nerve underdevelopment, abnormal brain midline structures, and pituitary gland hypoplasia.

Overview

Septo-optic dysplasia is a disorder that affects early brain development. This condition is typically defined as a combination of at least two of the following three features:

  • Underdevelopment (hypoplasia) of the nerves that carry visual information from the eye to the brain
  • Abnormal development of the structures that separate the right and left halves (the midline) of the brain
  • Hypoplasia of the hormone-producing gland (pituitary gland) at the base of the brain

The signs and symptoms of septo-optic dysplasia can vary widely among affected individuals. Less than half of people with septo-optic dysplasia have all three of the main features.

Because the signs and symptoms of septo-optic dysplasia can vary significantly, researchers have suggested that this condition may actually represent a spectrum of related conditions rather than a single disorder. Researchers have suggested various names for this spectrum, including "septo-optic-pituitary dysplasia," "septo-optic pituitary dysplasia complex," and "hypothalamo-pituitary-optic dysplasia."

Symptoms & Features

Optic Nerve Hypoplasia

In individuals with optic nerve hypoplasia, the optic nerves are often abnormally small and make fewer connections than usual between the eyes and the brain. As a result, affected individuals have impaired vision in one or both eyes. People with optic nerve hypoplasia can also have other eye abnormalities, including rapid, involuntary eye movements (nystagmus) and eyes that do not point in the same direction (strabismus).

Brain Midline Abnormalities

Abnormal development of the structures along the midline of the brain occurs in many people with septo-optic dysplasia. These structures include the corpus callosum, which is a band of tissue that connects the two halves of the brain, and the septum pellucidum, which separates the fluid-filled spaces in the brain. In affected individuals, these structures may form abnormally or fail to develop at all.

Additional brain abnormalities, such as slits or clefts in one or both halves of the brain (schizencephaly), may also be present. Depending on which structures are affected, abnormal brain development can lead to intellectual disabilities and other behavioral and neurological problems, including recurrent seizures (epilepsy), developmental delays, and autism spectrum disorder, which is characterized by impaired social skills and communication problems.

Pituitary Hypoplasia

Many people who have septo-optic dysplasia have an underdeveloped pituitary gland. Pituitary hypoplasia can lead to a shortage (deficiency) of essential hormones. These hormones help control growth, reproduction, and other critical body functions. In most cases, pituitary hypoplasia causes growth hormone (GH) deficiency, which results in slow growth and short stature.

Less commonly, individuals who have septo-optic dysplasia have panhypopituitarism, a condition in which the production of multiple hormones is impaired. Panhypopituitarism can be associated with slow growth, low levels of glucose in the blood (hypoglycemia), genital abnormalities, and problems with sexual development.

Frequency

Septo-optic dysplasia affects approximately 1 in 10,000 newborns.

Causes & Risk Factors

In most cases of septo-optic dysplasia, the cause of the disorder is unknown. Researchers suspect that a combination of genetic and environmental factors play a role in causing this disorder. Septo-optic dysplasia is more common in children born to young women who are pregnant for the first time. Children also have an increased risk of septo-optic dysplasia if they were exposed to alcohol or specific medications or drugs before birth, or if their mothers had certain viral infections while pregnant. A disruption in blood flow to certain areas of the brain during critical periods of development may also increase the risk of septo-optic dysplasia.

Variants (also called mutations) in a few genes that play important roles in embryonic development have been associated with septo-optic dysplasia. Genetic variants are more likely to be found in children born to older mothers who have had multiple pregnancies and in children who have additional findings.

Associated Genes

  • HESX1
  • OTX2
  • SOX2
  • SOX3

Inheritance

Septo-optic dysplasia is usually sporadic, which means that the condition typically occurs in people with no history of the disorder in their family.

Less commonly, septo-optic dysplasia has been found to run in families. Some familial cases appear to have an autosomal recessive pattern of inheritance, which means both copies of the gene in each cell must have a variant to cause the disorder. The parents of an individual with an autosomal recessive condition each carry one copy of the altered gene, but they typically do not show signs and symptoms of the condition.

In other cases, the condition has an autosomal dominant pattern of inheritance, which means one copy of the altered gene in each cell is sufficient to cause the disorder.

Other Names for This Condition

  • Combined pituitary hormone deficiency 5 (CPHD5)
  • De Morsier syndrome
  • Septo-optic dysplasia complex
  • Septo-optic-pituitary dysplasia complex
  • Septooptic dysplasia
  • SOD

Frequently Asked Questions

Diagnosis usually begins with a thorough physical examination and a detailed review of the child's medical history. Because the condition involves multiple systems, doctors often order an MRI of the brain to visualize the optic nerves and midline structures, which is the gold standard for confirming structural abnormalities. Additionally, blood tests are performed to measure hormone levels, specifically those produced by the pituitary gland, to check for deficiencies in growth hormone, thyroid-stimulating hormone, or cortisol. An ophthalmologist will also conduct a specialized eye exam to assess the size of the optic nerves and evaluate visual acuity.
Septo-optic dysplasia is usually sporadic, meaning it occurs randomly due to a new genetic mutation or environmental factor during early embryonic development, rather than being passed down from parents. However, in rare cases, it can be associated with specific chromosomal abnormalities or inherited genetic syndromes. Genetic counseling is recommended for families affected by the condition to assess the risk of recurrence. While the exact risk for future pregnancies is low for sporadic cases, a geneticist can review the family history and any available genetic testing results to provide a more personalized assessment of recurrence risk.
Vision loss due to optic nerve hypoplasia is generally permanent because the condition involves the underdevelopment of the nerve fibers themselves, which cannot be regenerated or repaired through surgery. However, corrective lenses can help address refractive errors like nearsightedness or farsightedness that may coexist with the condition. In cases where strabismus (misaligned eyes) is present, eye muscle surgery or patching therapy may be recommended to improve eye coordination and prevent amblyopia (lazy eye), although these treatments do not restore the vision lost due to the nerve hypoplasia itself. Early intervention with low-vision specialists is key to maximizing the child's functional independence.
If the pituitary gland is underdeveloped, it may fail to produce sufficient amounts of essential hormones, which can lead to significant growth delays and short stature. Children with this condition often require lifelong hormone replacement therapy, such as growth hormone injections, to support normal physical development. Beyond physical growth, hormonal imbalances can affect energy levels, bone density, and puberty timing. Regular monitoring by an endocrinologist is critical to adjust medication dosages as the child grows and to manage potential metabolic or cardiovascular risks associated with hormone therapy.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ